Results showed that CDKN2AIPNL was significantly upregulated in multiple tumors (e.g., LIHC, UVM, BRCA, LUAD) and downregulated in others (e.g., KICH, KIRP, THCA), with high tumor specificity. Here, XTBD1 is linked to neoplasm.